ArticleJournal of breast cancer2025
Radiotherapy Boost to Clinically Positive Internal Mammary Lymph Nodes: An Effective Non-Surgical Alternative?
Article in Journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of radiation therapy (RT) boost sequences and doses to internal mammary (IM) lymph nodes (LNs) on oncologic outcomes and toxicity in patients with clinically IMLN-positive breast cancer.
methodsTwenty-six patients with positive IMLNs at diagnosis who were treated between 2013 and 2022 were retrospectively evaluated. After systemic therapy and surgery, RT was applied to the whole breast or chest wall, including the axillary, supraclavicular, and IM lymphatics. An RT boost to the IMLNs was administered either sequentially or as a simultaneous integrated boost (SIB). Treatment outcomes, prognostic factors, and toxicity profiles were analyzed.
resultsA complete response (CR) and partial response (PR) in metastatic IMLNs were observed in 17 patients (65.4%) and 5 patients (19.2%) following systemic therapy, respectively. One patient (3.8%) had stable disease, while two patients (7.7%) experienced disease progression in the IMLNs.After a median follow-up of 67 months, regional recurrence, distant metastasis, or both occurred in 1 (3.8%), 1 (3.8%), and 2 (7.7%) patients, respectively. The 5-year overall survival (OS) and disease-free survival (DFS) rates were 86.7% and 76.4%, respectively. The absence of extracapsular extension in axillary LNs was associated with improved OS and DFS. A CR or PR to systemic treatment in IMLNs was associated with improved DFS only. The boost sequence had no significant effect on survival, organ-at-risk doses, or cardiac toxicity.
conclusionAn RT boost to IMLNs without surgical resection provides excellent oncologic outcomes with acceptable toxicity. While the SIB technique reduces the number of treatment fractions, it did not result in superior oncologic outcomes compared to the sequential boost. Further prospective studies are needed to investigate the role of RT boost sequencing to the IMLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.